Ada and Pfizer tech tackles severe Covid

Digital health company Ada Health has launched a digital care journey to help people understand if they meet current criteria for progression to severe COVID-19.

The COVID-19 Care Journey platform connects the user with a health care provider for evaluation of their COVID-19 symptoms and treatment options.

Almost 200 million Americans have one or more risk factors that puts them at high risk of progression to severe COVID-19.

However, many people are not aware of this increased risk.

The coronavirus remains the third leading cause of death in the US, currently causing an average of over 400 deaths a day.

Ada CEO and co-founder, Daniel Nathrath, said:

“Tackling conditions such as COVID-19 swiftly and effectively is imperative to improving people’s wellbeing and livelihoods, as well as alleviating the immense pressure it puts on global health systems and economies.

“The Ada COVID-19 Care Journey aims to significantly reduce the time from testing to treatment for users, and we firmly believe that it has the potential to improve health outcomes for millions.”

Developed in partnership with Pfizer, The COVID-19 Care Journey hosts an independent telehealth and ePharmacy provider option.

Users can learn whether they are at high risk of developing severe COVID-19, assess their health care provider options and connect to a health care provider through telehealth, to assess their symptoms and treatment eligibility.

They can also obtain a prescription for an authorised oral treatment for COVID-19 for same-day pick up at a local pharmacy.

JoyL Silva, Global and U.S. Antiviral Franchise Lead, Pfizer, said:

“Connected digital health initiatives are a key step in lower cost, faster, more equitable and more convenient access to healthcare.

“Our collaboration with Ada is designed to educate patients on high-risk factors for severe COVID-19 and introduce choices for people to access a provider and learn about treatment options.

“We are excited to be a part of this COVID-19 Care Journey and for its potential to help reach some of the most vulnerable patients across the United States.”